Prestige Consumer Healthcare (NISE: PBH) updated its financial statements for FI19 on Thursday. The company secured earnings per share from $ 2.84 to $ 2.92 for that period, compared to Thomson Reuters estimated revenue of $ 2.86. The company issued instructions for revenue of $ 985-995 million, compared to an estimated $ 986.48 million revenue from a consensus.
Numerous research firms recently commented on PBH. ValuEngine lowered Prestige Consumer Healthcare's rating from rating to rating on sales in the survey on Friday. Jefferies Financial Group set a target price of $ 38.00 for Prestige Consumer Healthcare on Thursday, August 2nd, and gave it a rating firm in the investigation. DA Davidson increased its target price for Prestige Consumer Healthcare's $ 38.00 and gave the company a neutral rating in its research report on Monday, November 5th. In the end, Zacks Investment Research reiterated its rating for Prestige Consumer Healthcare in a survey Wednesday. An investment analyst rated the rating with sales ratings, three received a rating for maintenance, and four issued a rating for buying a company. The stock currently has a consensus rating of Hold and a target price for a consensus of $ 72.40.
Prestige Consumer Healthcare opened on Friday 37.98 dollars. The company has a debt ratio of 1.59 in capital, a quick ratio of 1.38 and a current ratio of 2.15. Prestige Consumer Healthcare has a 12-month minimum of $ 27.84 and a 12-month maximum of $ 48.24. The company has a market cap of $ 2.03 billion, a P / E ratio of 14.72, a P / E / G ratio of 1.94 and a beta of 1.04.
Prestige Consumer Healthcare (NISE: PBH) published data on the fourth earnings on Thursday, November 1st. The company posted a gain of $ 0.65 per share for a quarter, leading to a Thomson Reuters consensus estimate of $ 0.63 for $ 0.02. Prestige Consumer Healthcare had a net margin of 33.38% and a return on equity of 11.82%. The company had a revenue of $ 239.36 million per quarter, compared with a consensus estimate of $ 236.28 million. During the same quarter of the previous year, the company realized earnings per share of 0.61 dollars. Operating revenues were down by 7.2% annually. On average, security research analysts expect Prestige Consumer Healthcare to publish 2.88 EPS for the current fiscal year.
In other news of Prestige Consumer Healthcare, EVP Timothy Connors sold 74,707 shares of the company on Wednesday, November 14. The shares were sold at an average price of $ 38.96 for a total transaction of $ 2,910,584.72. After the transaction, the executive vice president now owns 95,382 shares in the company, valued at $ 3,716,082.72. The transaction was detected in a submissions with the SEC, which is available through this link. Corporate insiders own 1.14% of shares of the company.
NOTIFICATION OF ILLEGAL ACTIVITIES: "Prestige Consumer Healthcare (NISE: PBH) Updates to FI19 Earnings for Employment" was originally published by Marea Informative and owned by Marea Informative. If you are reading this story on another website, it is unlawfully stolen and published by violation of US and international copyright laws. You can view the legal version of this story at https: //vvv.mareainformativa.com/2018/11/16/prestige-consumer-healthcare-pbh-releases-fi19-earnings-guidance-updated-updated.html.
Profile of Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, produces, markets, distributes and sells cleaning and care products for households in North America, Australia and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare and Household Cleaning.
Further reading: Hedge funds
Accept news and ratings for everyday Prestige user health – Enter your email address below to get a concise daily overview of the latest news and analysts for Prestige Consumer Healthcare and related companies with the FREE Daily MarketBeat.com newsletter.